Post-Marketing Surveillance in Generic Drugs: What’s Required? – clinical safety and pharmacovigilance Post-Marketing Surveillance in Generic Drugs: What’s Required? The post-marketing surveillance (PMS) of generic drugs is critical in ensuring clinical safety and pharmacovigilance. Regulatory authorities across the globe require pharmaceutical companies to have robust processes in place for monitoring the safety and efficacy of drug products after they have been marketed. This guide aims to provide regulatory affairs professionals, pharmacovigilance experts, and compliance officers with actionable insights into the requirements and best practices associated with PMS in various jurisdictions, including the US, EU, and India. How to Establish a…

Combining PMS with Real-World Evidence (RWE) – pharmaceutical industry regulatory compliance Combining PMS with Real-World Evidence (RWE) – pharmaceutical industry regulatory compliance Post-Marketing Surveillance (PMS) is a critical component in monitoring the safety and effectiveness of pharmaceutical products following their approval. The integration of Real-World Evidence (RWE) with PMS processes has become increasingly relevant, providing insights that can significantly enhance regulatory compliance efforts. This article details the methods and strategies for effectively combining PMS with RWE, ensuring adherence to global regulatory frameworks including those set by the FDA, EMA, and other health authorities. How to Structure Your Post-Marketing Surveillance Program…

PMS Responsibilities in MAH-PV Agreements – Pharmaceutical Industry Regulatory Compliance PMS Responsibilities in MAH-PV Agreements – Pharmaceutical Industry Regulatory Compliance The post-marketing surveillance (PMS) phase of drug development is crucial for ensuring ongoing safety and efficacy of pharmaceutical products. Within this framework, the obligations of Marketing Authorization Holders (MAHs) and their agreements with pharmacovigilance (PV) service providers are defined by various regulatory standards globally, such as those set forth by the FDA, EMA, and ICH. This article will provide a comprehensive guide on how to navigate these complex regulatory landscapes to maintain compliance in the pharmaceutical industry. How to Understand…

Role of CROs and PV Partners in Conducting PMS Studies – regulatory compliance in pharmaceutical industry Role of CROs and PV Partners in Conducting PMS Studies – regulatory compliance in pharmaceutical industry Post-Marketing Surveillance (PMS) is a critical component of drug safety and efficacy monitoring in the pharmaceutical industry. Conducting PMS studies appropriately ensures compliance with global regulatory expectations. This manual outlines the role of Contract Research Organizations (CROs) and Pharmacovigilance (PV) partners in aligning with these regulations, enhancing their effectiveness in ensuring drug safety. How to Engage CROs Effectively for PMS Studies Engaging a CRO for post-marketing surveillance requires…

Common PMS Deficiencies Identified in Regulatory Audits – pharmaceutical industry regulatory compliance Common PMS Deficiencies Identified in Regulatory Audits within the Pharmaceutical Industry The regulatory landscape is continually evolving, and adherence to Post-Marketing Surveillance (PMS) requirements is critical for pharmaceutical companies to ensure patient safety and maintain compliance. This article serves as a how-to manual for regulatory affairs, pharmacovigilance, and drug safety professionals, highlighting common deficiencies identified during regulatory audits and providing actionable insights into enhancing compliance with global standards. Organizations must not only recognize common pitfalls in their PMS processes but also develop strategies to overcome these issues effectively….

Post-Marketing Surveillance Requirements by Region: Best Practices and Compliance Checklist Post-Marketing Surveillance Requirements by Region: Best Practices and Compliance Checklist How to Understand Post-Marketing Surveillance Requirements Globally Post-marketing surveillance (PMS) is crucial for the ongoing assessment of the safety and efficacy of medicinal products once they are available on the market. Different regions have varying regulatory frameworks governing PMS, which can complicate compliance for bank compliance consulting firms involved in pharmacovigilance activities. This section will provide an overview of post-marketing surveillance requirements across key jurisdictions, including the United States (FDA), Europe (EMA), United Kingdom (MHRA), and India (DCGI). The U.S….

Common Mistakes in Post-Marketing Surveillance Requirements by Region and How to Avoid Them – regulatory science master’s Common Mistakes in Post-Marketing Surveillance Requirements by Region and How to Avoid Them Post-marketing surveillance is a critical aspect of pharmacovigilance, ensuring ongoing safety and efficacy of pharmaceutical products in the market. Regulatory authorities worldwide, including the FDA, EMA, and MHRA, have established stringent guidelines for this process. This article serves as a comprehensive manual for regulatory professionals, detailing common mistakes made in post-marketing surveillance requirements by region and offering actionable guidance to avoid them. How to Understand Post-Marketing Surveillance Requirements Globally Understanding…

Step-by-Step Implementation Guide to Post-Marketing Surveillance Requirements by Region – clinical regulatory affairs Step-by-Step Implementation Guide to Post-Marketing Surveillance Requirements by Region This article serves as a comprehensive manual for understanding and implementing post-marketing surveillance requirements across various regions, including the US, EU, and India. As regulatory agencies tighten their scrutiny on pharmacovigilance practices, the importance of robust post-marketing surveillance cannot be overstated. It is essential for professionals involved in clinical regulatory affairs to remain compliant with the changing landscape of regulations governing drug safety and efficacy. Here, we provide actionable guidance aligned with the frameworks set forth by the…

KPI and Performance Metrics for Post-Marketing Surveillance Requirements by Region Programs – clinical and regulatory affairs KPI and Performance Metrics for Post-Marketing Surveillance Requirements by Region Programs Post-marketing surveillance is crucial to ensure the ongoing safety and effectiveness of pharmaceutical products. Understanding the Key Performance Indicators (KPIs) and performance metrics is essential for professionals engaged in clinical and regulatory affairs. This article will provide a comprehensive guide on establishing and evaluating KPIs tailored to the specific requirements of post-marketing surveillance across various regions, including the US, EU, India, and beyond. How to Establish KPIs for Post-Marketing Surveillance Establishing relevant KPIs…

Outsourcing vs In-House Models for Post-Marketing Surveillance Requirements by Region – regulatory consulting pharma Outsourcing vs In-House Models for Post-Marketing Surveillance Requirements by Region Pharmaceutical companies are tasked with ensuring their products are both safe and effective throughout their lifecycle, a responsibility that extends into the post-marketing phase. In this article, we will explore the regulatory consulting dynamics between outsourcing and in-house models for post-marketing surveillance (PMS) requirements across different regions including the United States, Europe, and India. Our focus will be on the strategies available to regulatory affairs professionals, specifically regarding how they can optimize their PMS efforts while…